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Statin use and breast cancer survival: a
nationwide cohort study in Scotland
Úna C. Mc Menamin1,4*, Liam J. Murray1,3, Carmel M. Hughes2 and Chris R. Cardwell1
Abstract
Background: Preclinical evidence suggests that statins could delay cancer progression. Previous epidemiological
findings have been inconsistent and some have been limited by small sample sizes, as well as certain time-related
biases. This study aimed to investigate whether breast cancer patients who were exposed to statins had reduced
breast cancer-specific mortality.
Methods: We conducted a retrospective cohort study of 15,140 newly diagnosed invasive breast cancer patients
diagnosed from 2009 to 2012 within the Scottish Cancer Registry. Dispensed medication usage was obtained from
linkages to the Scottish Prescribing Information System and breast cancer-specific deaths were identified from
National Records of Scotland Death Records. Using time-dependent Cox regression models, hazard ratios (HR) and
95 % confidence intervals (CI) were calculated for the association between post-diagnostic exposure to statins
(including simvastatin) and breast cancer-specific mortality. Adjustments were made for a range of potential
confounders including age at diagnosis, year of diagnosis, cancer stage, grade, cancer treatments received,
comorbidities, socioeconomic status and use of aspirin.
Results: A total of 1,190 breast cancer-specific deaths occurred up to January 2015. Overall, after adjustment for
potential confounders, there was no evidence of an association between statin use and breast cancer-specific death
(adjusted HR 0.93, 95 % CI 0.77, 1.12). No significant associations were observed in dose–response analyses or in
analysis of all-cause mortality. For simvastatin use specifically, a weak non-significant reduction in breast cancer-specific
mortality was observed compared to non-users (adjusted HR 0.89, 95 % CI 0.73, 1.08). Statin use before diagnosis was
weakly associated with a reduction in breast cancer-specific mortality (adjusted HR 0.85, 95 % CI 0.74, 0.98).
Conclusion: Overall, we found little evidence of a protective association between post-diagnostic statin use and
cancer-specific mortality in a large nation-wide cohort of breast cancer patients. These findings will help inform the
decision whether to conduct randomised controlled trials of statins as an adjuvant treatment in breast cancer.
Keywords: Statins, Breast Cancer, Scotland, Pharmacoepidemiology
Background
Statins (3-hydroxy-3-methylglutaryl coenzyme A reduc-
tase inhibitors) are cholesterol-lowering drugs widely
prescribed in the primary and secondary prevention of
cardiovascular disease. Growing laboratory evidence sug-
gests that statins may also have anti-cancer effects [1]
through inhibition of cellular proliferation [2], induction
of apoptosis [3] and suppression of tumour cell migration
[4]. In breast cancer, the anti-proliferative effects of statins
have been demonstrated both in vitro [5] and in vivo [6],
and are particularly strong for lipophilic statins (such as
simvastatin) [6]. Interestingly, preclinical studies of breast
cancer have indicated that the reduction in cell prolifera-
tion may be more marked in oestrogen receptor (ER) −
negative cells [5], suggesting that ER-negative tumours
may be more sensitive to the potential anti-cancer effects
of statins. Moreover, the antiproliferative and proapoptotic
potential for statins have been demonstrated in breast
cancer clinical trials of lipophilic [7, 8] and hydrophilic
statins [9].
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Statin use is associated with a reduction in cancer mor-
tality [10] and thus far, a number epidemiological studies
have investigated the association between statin use after
breast cancer diagnosis and breast cancer-specific mortal-
ity (or recurrence). In a large Finnish study of newly diag-
nosed breast cancer patients, a significant 54 % reduction
in breast cancer-specific mortality was observed, which
was dose-dependent and similar for both hydrophilic and
lipophilic statins [11]. This investigation however, against
recommendations [12], used unlagged analyses (i.e. did
not exclude medication use immediately prior to death
which could be influenced by impending death), thus any
observed protective association between statin use and
breast cancer mortality could partly reflect not starting
statin use, or the discontinuation of statin use, in fatally ill
cancer patients [13]. There was also a lack of adjustment
for important potential confounders such as other medi-
cation use and comorbidities [11]. A second study in-
cluded breast cancer patients diagnosed in England and
we previously reported a weak non-significant 16 % reduc-
tion in breast cancer death in statin users after diagnosis
which appeared slightly more marked for the highly lipo-
philic statin simvastatin [14]. The relationship between
statin use after diagnosis and breast cancer mortality how-
ever did not follow a clear dose–response and was attenu-
ated in fully adjusted analyses [14]. In a large Danish
cohort study of women diagnosed with stage I–III breast
cancer, using as recommended, an exposure lag, a 20 % re-
duction in risk of cancer recurrence was observed among
users of statins after diagnosis. The reduction in breast
cancer recurrence was also observed in lipophilic statin
users (adjusted HR 0.70, 95 % CI 0.53 to 0.92), whereas no
association was observed for hydrophilic statins [15].
Other investigations of statin use and breast cancer recur-
rence have shown little evidence of associations [16, 17],
however they were relatively small in size [16–18], and
some [18] had potential for immortal time bias [19].
Despite previous studies not being conclusive, there have
been calls for clinical trials [20]. Therefore, there is a need
for additional well conducted population-based studies to
inform the conduct of future clinical trials of statins (par-
ticularly simvastatin) in breast cancer patients. Therefore,
in a large nation-wide study of newly diagnosed breast
cancer patients, we aimed to evaluate the association be-
tween statin use after breast cancer diagnosis and breast
cancer-specific mortality and to determine whether the
association differs by drug solubility. We also aimed to
determine if the association was modified by breast
cancer estrogen receptor status.
Methods
Data sources
The study utilised linkages between national datasets from
Scotland including the Scottish Cancer Registry (SMR06),
the Prescribing Information System, the General/Acute
Inpatient and Day Case dataset (SMR01), the Outpatient
Attendance dataset (SMR00) and the National Records of
Scotland Death Records. The Scottish Cancer Registry
captures information on all cancers occurring in Scotland
including date and site of primary cancer diagnosis, stage,
grade and treatment data. The Prescribing Information
System (available from January 2009 to January 2015)
holds all medicines dispensed in the community in
Scotland. The General/Acute Inpatient and Day Case
dataset (available from January 1999 to January 2015) con-
tains information on hospital diagnoses and operations
and the Outpatient Attendance dataset (available from
January 1999 to January 2015) contains diagnosis and pro-
cedures from new and follow up appointments at out-
patient clinics. The National Records of Scotland Death
Records contain date and cause of death up to January
2015. Linkages between data sources were conducted
using the Community Health Index number (a unique
number unique to individuals in Scotland).
Study population
A cohort of newly diagnosed invasive breast cancer pa-
tients was identified on the basis of a Scottish Cancer
Registry recorded primary diagnosis of breast cancer
(ICD code C50) between January 2009 and December
2012. Cohort members with previous Scottish Cancer
Registry cancer diagnosis (after January 1999), apart
from in situ neoplasms and non-melanoma skin cancers,
were excluded. Deaths were identified from National Re-
cords of Scotland with coverage up to 1st January 2015
(or from Scottish Cancer Registry death records) with
breast cancer-specific deaths defined as those with breast
cancer as the underlying cause of death (ICD code C50).
Deaths in the first year after breast cancer diagnosis were
removed (sensitivity analysis was conducted varying this
interval) as it is likely that these patients had stage IV dis-
ease and it seemed unlikely that short term post-diagnostic
medication usage could influence such deaths, therefore
follow-up started one year after diagnosis. The patients
were followed from one year after breast cancer diagnosis
to death, the date they left Scotland or 1st January 2015.
Study design
Exposure data
Statins dispensed in the community (identified from the
Prescribing Information System) consisted of all medica-
tions in the Statins section of the British National Formu-
lary (BNF) [21] (Section 2.12). A quantity of 28 tablets was
assumed for the less than 0.1 % of dispensed prescriptions
where quantity was assumed incorrect. Statin use was in-
vestigated as a time varying covariate [19] (patients were
initially considered non-users and then users after a lag of
6 months after their first statin prescription). The use of a
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lag is recommended [12] and was used to exclude prescrip-
tions in the six months prior to death as these may reflect
changes due to end of life care (in sensitivity analyses the
duration of this lag was varied). Medications may be
withdrawn from cancer patients in whom death is sus-
pected to be imminent and unlagged time-varying covari-
ate analysis can bias results due to reverse causality [13].
Dose–response analyses were conducted with individuals
considered non-users prior to 6 months after first use, a
short term user between 6 months after first use and
6 months after the 12th prescription and a longer term
user after this time. Further analyses was conducted by
drug solubility including lipophilic (simvstatin and fluvas-
tatin) and hydrophilic (atorvastatin, rosuvastatin and prav-
astatin) statins. Separate analysis investigated the influence
of simvastatin use compared to non-use of simvastatin.
Covariates
Data available from the Scottish Cancer Registry in-
cluded AJCC cancer stage [22], histological grade (grade
1, 2 or 3), hormone receptor status (including estrogen,
progesterone and HER2 status) and cancer treatments
(including surgery, chemotherapy and radiotherapy in
the six months after diagnosis). Comorbidities that con-
tribute to the Charlson index were determined prior to
diagnosis based upon ICD10 diagnosis codes, as de-
scribed previously [23], in Scottish hospital inpatient
(SMR01) and outpatient data (SMR00). A measure of so-
cioeconomic status measure was determined using the
2009 Scottish Index of Multiple Deprivation based upon
postcode of residence [24] which comprises super out-
put area (SOA) level measures of multiple deprivation
(based on residential postcodes) and is made up of seven
SOA level domain indices. Information on hormone
therapy use (including tamoxifen and aromatase inhibi-
tor) was obtained from dispensed prescription records.
Similarly, low-dose aspirin use, metformin and hormone
replacement therapy (HRT) use (either estrogen alone or
combination) were determined from dispensing records.
Statistical analysis
In the main analysis, time-dependent Cox regression
models were used to calculate hazard ratios for breast
cancer-specific death (HRs) and 95 % confidence intervals
(95 % CIs) for post-diagnostic statin users (regardless of
pre-diagnostic statin use) compared with non-users using
a time varying covariate as described previously. Adjusted
analyses were conducted including the following potential
confounders: age at diagnosis (continuous), year of diag-
nosis (in 1-year bands), socioeconomic status (in fifths),
grade (1, 2 or 3), stage (1, 2, 3 or 4), surgery (yes or no
within 6 months), radiotherapy (yes or no within 6 months),
chemotherapy (yes or no within 6 months), aromatase in-
hibitor (yes or no as a time varying covariate), tamoxifen
(yes or no as a time varying covariate), comorbidities
(yes or no prior to diagnosis, including acute myocardial
infarction, congestive heart failure, peripheral vascular
disease, cerebral vascular accident, pulmonary disease,
peptic ulcer, liver disease, diabetes, renal disease), hor-
mone replacement therapy use (yes or no in year prior
to diagnosis), aspirin and metformin usage (yes or no
after post-diagnosis, as time varying covariates). Analyses
were conducted by number of dispensed statin prescrip-
tions and repeated for all-cause mortality. Subgroup ana-
lyses were conducted by cancer stage, year of diagnosis and
estrogen receptor status. Separate sensitivity analysis was
conducted by additionally adjusting for tumour hormone
receptor status and increasing the lag from six months to
1 year, thereby excluding prescriptions in the year prior to
death. A simplified analysis was also conducted using Cox
regression to compare statin users to statin non-users in
the first year after breast cancer diagnosis in individuals liv-
ing more than 1 year after diagnosis; this controls immortal
time bias [25] without requiring time varying covariates.
An analysis was conducted based upon statin prescriptions
in the year prior to diagnosis, regardless of post-diagnostic
statin use (excluding patients diagnosed in 2009 for whom
a full year of prescription records prior to diagnosis may
not be available), not excluding deaths in the first year after
diagnosis. An adjusted analysis for pre-diagnostic statin use
was first conducted omitting stage, grade, cancer treatment
from adjustments for potential confounders to avoid over-
adjustment [26, 27], as these could be on the causal path-
way for breast cancer-specific mortality. A separate analysis
was also conducted using the time varying covariate ap-
proach with breast cancer-specific death as the outcome,
adjusting for the competing risk of deaths from other
causes, using competing-risks regression based on Fine and
Gray’s proportional subhazards model [28]. Similar sensitiv-
ity analyses were carried out for all-cause mortality. A fur-
ther analysis was conducted for only cardiovascular deaths
(where the underlying cause of death was ICD 10 codes
I0-99, G45, Q20-26, F01 or equivalent ICD-9 codes)
and for all deaths excluding these cardiovascular deaths.
Results
Patient cohort
A total of 15,140 newly diagnosed breast cancer patients
without a prior cancer history and with at least one year
of follow-up were identified for inclusion, in which there
was on average 4 years of follow-up after diagnosis (sd = 1,
minimum= 1, maximum= 6 years). Patient characteristics
by statin use are shown in Table 1. Statin users were more
likely to be older and to have a lower socioeconomic sta-
tus. Stage and grade were generally similar by statin use,
but a slightly smaller proportion of statin users compared
with non-users had poorly differentiated tumours (31 %
versus 35 %, respectively). Statin users were less likely to
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Table 1 Characteristics of breast cancer patients by statin use
Statin use in the year prior to diagnosisa Statin use in the year after diagnosisb
User Non-user User Non-user
n % n % n % n %
[n = 3,031] [n = 9,200] [n = 4,233] [n = 10,907]
Year of diagnosis
2009 861 23.8 2,811 24.4 <0.001
2010 994 32.8 2,990 32.5 0.73 915 25.2 2,811 24.4
2011 1,005 33.2 3,090 33.6 920 25.4 2,929 25.4
2012 1,032 34.0 3,120 33.9 928 25.6 2,965 25.7
Age at diagnosis
<50 69 2.3 2098 22.8 <0.01 93 2.4 2,741 23.9 <0.001
50–59 322 10.6 2,516 27.3 447 12.3 3,246 28.2
60–69 989 32.6 2,365 25.7 1,264 34.9 3,008 26.1
70–79 911 30.1 1,242 13.5 1,082 29.9 1,508 13.1
80–89 626 20.7 759 8.3 636 17.5 819 7.1
≥90 114 3.8 220 2.4 102 2.8 194 1.7
AJCC stage
1 1086 35.8 3556 38.7 0.43 1400 38.6 4541 39.4 <0.001
2 1053 34.7 3415 37.1 1290 35.6 4421 38.4
3 353 11.6 1033 11.2 425 11.7 1337 11.6
4 208 6.9 492 5.3 141 3.9 443 3.8
Missing 331 10.9 704 7.7 368 10.2 774 6.7
Grade
1 366 12.1 1089 11.8 <0.001 466 12.9 1363 11.8 0.003
2 1335 44 4008 43.6 1647 45.4 5139 44.6
3 900 29.7 3172 34.5 1130 31.2 4125 35.8
Missing 430 14.2 931 10.1 381 10.5 889 7.7
Socioeconomic status
1 (most deprived) 676 22.3 1419 15.4 <0.001 776 21.4 1,736 15.1 <0.001
2 709 23.4 1682 18.3 825 22.8 2,089 18.1
3 582 19.2 1,914 20.8 723 20.0 2,391 20.8
4 587 19.4 2,025 22.0 703 19.4 2,582 22.4
5 (least deprived) 477 15.7 2,159 23.5 597 16.5 2,717 23.6
Treatment (within 6 months)
Surgery 2,163 71.4 7,322 79.6 <0.001 2,808 77.5 9,592 83.3 <0.001
Radiotherapy 1,219 40.2 3,278 35.6 <0.001 1,486 41.0 4,080 35.4 <0.001
Chemotherapy 546 18.0 3,566 38.7 <0.001 705 19.5 4,722 41.0 <0.001
Comorbidity prior to diagnosis
Acute myocardial infarction 227 7.5 63 0.7 <0.001 246 6.8 59 0.5 <0.001
Congestive heart failure 144 4.8 96 1.0 <0.001 149 4.1 76 0.7 <0.001
Peripheral vascular disease 105 3.5 46 0.5 <0.001 114 3.1 50 0.4 <0.001
Cerebral vascular accident 282 9.3 120 1.3 <0.001 287 7.9 116 1.0 <0.001
Pulmonary disease 288 9.5 449 4.9 <0.001 305 8.4 499 4.3 <0.001
Petptic ulcer 73 2.4 100 1.1 <0.001 86 2.4 119 1.0 <0.001
Liver disease 8 0.3 13 0.1 0.34 8 0.2 17 0.1 0.16
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receive surgery, chemotherapy and tamoxifen; how-
ever they were more likely to receive radiotherapy and
aromatase inhibitors. A greater proportion of statin
users compared to non-users had comorbidities (particu-
larly for cerebrovascular disease, diabetes and myocardial
infarction) and were users of low-dose aspirin and
metformin.
Association between statin use after diagnosis and
survival
The main findings are displayed in Table 2. After adjust-
ment for potential confounders, there was little evidence
of an association between statin use after diagnosis (re-
gardless of pre-diagnostic use) and breast cancer-specific
mortality (adjusted HR 0.95, 95 % CI 0.79, 1.15). There
was also no evidence of a dose–response association
when post-diagnostic exposure was investigated by in-
creasing number of prescriptions after diagnosis. For
post-diagnostic simvastatin use specifically, a weak non-
significant reduction in breast cancer-specific mortality
was observed compared to non-users of simvastatin (ad-
justed HR 0.89, 95 % CI 0.73, 1.08), Table 2. Results were
similar for use of any lipophilic statin after diagnosis
compared to non-use (adjusted HR 0.90, 95 % CI
0.74,1.11) and were slightly less marked for users of
hydrophilic statins after diagnosis compared to non-
users (adjusted HR 0.97, 95 % CI 0.76, 1.24). In analysis
of all-cause mortality, statin use was weakly associated
with a (non-significant) reduction in mortality in ad-
justed analysis (adjusted HR 0.88, 95 % CI 0.76, 1.01);
however no dose–response relationship was observed by
increasing number of prescriptions, Table 2. Results were
similar for use of lipophilic statins, including simvastatin
(adjusted HR 0.87, 0.75, 1.01), and hydrophilic statin use
after diagnosis, Table 2.
Association between statin use before diagnosis and
survival
Results for statin use in the year preceding diagnosis are
shown in Table 3. In adjusted models, statin use before
diagnosis (regardless of post-diagnostic use) was weakly
associated with a reduction in breast cancer-specific
mortality (adjusted HR 0.85, 95 % CI 0.74, 0.98). Results
were similar for users simvastatin after diagnosis com-
pared to non-users of simvastatin (adjusted HR 0.87,
95 % CI 0.75, 1.02) and in analysis of any lipophilic sta-
tin use (adjusted HR 0.88, 95 % CI 0.76, 1.02), Table 3.
Results were slightly attenuated in analysis of hydrophilic
statins use compared to non-use (adjusted HR 0.90, 95 %
CI 0.75, 1.09). For all-cause mortality, a significant reduc-
tion in risk was observed in adjusted models (adjusted HR
0.75, 95 % CI 0.67, 0.84) and results were similar for
simvastatin use compared to non-use (adjusted HR 0.83,
95 % CI 0.74, 0.92), Table 3.
Sensitivity\secondary analyses
Sensitivity\secondary analyses results are shown in Table 4.
In comparison to the main analysis of statin use after diag-
nosis and breast cancer-specific mortality, stratification by
cancer stage did not materially alter effect estimates. The
observed associations for post-diagnostic statin use were
similar in patients diagnosed with ER positive tumours
and after additional adjustment for ER, PR and human
epidermal growth factor 2 (HER2) status. There was a sug-
gestion of a modest reduction in breast cancer-specific
mortality risk in patients diagnosed in 2009–2010 (ad-
justed HR 0.77, 95 % CI 0.60, 0.98); however there was no
evidence of a statistical interaction. Results for post-
diagnostic statin use and breast cancer-specific mortality
remained unchanged after increasing the lag from six
months to 1 year and after adjustment for competing risks
of death, Table 4. There were also no marked differences
in associations when analysis was repeated in a simple
analysis of any statin use (or simvastatin use) compared to
non-use in the year after diagnosis. For all-cause mortality,
similar estimates were produced across a number of sensi-
tivity analyses, Table 4. Similar results were also obtained
in analyses of cardiovascular and non-cardiovascular
deaths.
Table 1 Characteristics of breast cancer patients by statin use (Continued)
Diabetes 395 13.0 115 1.3 <0.001 422 11.6 129 1.1 <0.001
Renal disease 101 3.3 94 1.0 <0.001 100 2.8 85 0.7 <0.001
Medication use in year after diagnosis
Low-dose aspirinc 1,406 46.4 561 6.1 <0.001 1,617 44.6 737 6.4 <0.001
Aromatase inhibitors 1,840 60.7 3,658 39.8 <0.001 2,258 62.3 4,550 39.5 <0.001
Tamoxifen 850 28.0 4,038 43.9 <0.001 1,080 29.8 5,262 45.7 <0.001
Metformin 1,201 33.1 1183 10.3 <0.001 440 14.5 98 1.1 <0.001
aAnalysis includes breast cancer patients who have more than 1 year of records prior to diagnosis and excludes patients diagnosed 2009 for whom full
medication records not available in the year prior to diagnosis. bPost-diagnostic statin use in the year after diagnosis among breast cancer patients who lived
more than 1 year after diagnosis. cLow-dose aspirin use in year after diagnosis for statin use in year after diagnosis columns, low-dose aspirin use in year prior to
diagnosis for statin use in year prior to diagnosis columns
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Discussion
In a large cohort of cancer registry confirmed breast
cancer patients, we found little evidence of a reduction
in breast cancer-specific mortality associated with statin
use after diagnosis, however, our data could not rule out
a weak protective effect of statins on breast cancer mor-
tality, consistent with the confidence intervals observed
(adjusted HR 0.95, 95 % CI 0.79, 1.15). Associations
remained similar in analysis of dose–response and across
a number of sub-group and sensitivity analyses.
Statin use has been associated with a 15–20 % reduc-
tion in all-cancer mortality [10, 29] but few studies have
investigated the influence of statins on breast cancer-
specifc mortality. Our main results for statin use after
diagnosis are inconsistent with findings from a Finnish
study [11] which observed a substantial reduction in
breast cancer mortality risk with statin use after diagno-
sis (adjusted HR 0.46, 95 % CI 0.38, 0.55) in a large co-
hort of breast cancer patients, with similar findings
observed in analysis of all-cause mortality and in analysis
by statin type. Statin use however was not lagged in this
study, thus, the reduction in risk observed with post-
diagnostic statin use may be affected by the possible dis-
continuation, or lack of initiation, of statin use in some
patients due to imminent death. The authors were also
unable to adjust for potential confounding by other
medication use in their analyses (such as HRT and low
dose aspirin [30]), in addition to comorbidities. In all
analyses, we lagged medication use, as recommended
[12], after diagnosis by 6 months and this period was
varied in sensitivity analysis. Our results are not incon-
sistent with our previous study of a large English cohort
of breast cancer patients diagnosed with linkages to the
Clinical Practice Research Datalink (CPRD) [14]. We
previously reported a weak reduction in the rate of
breast cancer-specific mortality with post-diagnosis sta-
tin use (adjusted HR 0.84, 95 % CI 0.68, 1.04) and simva-
statin use (adjusted HR 0.79 95 % CI 0.63, 1.00) [14], but
our results from Scotland are weaker for both overall
use (adjusted HR 0.93, 95 % CI 0.77, 1.12) and simvastatin
use (adjusted HR 0.87, 95 % CI 0.72, 1.07). The findings of
a more marked (albeit non-significant) reduction in cancer
Table 2 Association between statin use after diagnosis and breast cancer-specific and all-cause mortality in patients with breast cancer
Breast cancer
mortality
Patients Person
years
Age-adjusted HR (95 % CI) P Adjusteda HR (95 % CI) P
[n = 15,140] [n = 13,060]
Breast cancer mortality
Statin non-user 855 10,907 30,852 1.00 (ref. cat.) 1.00 (ref. cat.)
Statin user 335 4,233 10,421 0.87 (0.76,0.99) 0.04 0.95 (0.79,1.15) 0.62
1-12 prescriptions 201 1,358 5,713 0.91 (ref. cat.) 0.22 0.94 (0.75,1.18) 0.61
≥12 prescriptions 134 2,875 4,708 0.82 (0.68,0.99) 0.04 0.97 (0.75,1.25) 0.79
Simvastatin non-user 966 12,115 33,845 1.00 (ref. cat.) 1.00 (ref. cat.)
Simvastatin user 224 3,025 7,428 0.82 (0.71,0.95) 0.01 0.89 (0.73,1.08) 0.24
Lipophilic non-user 964 12,110 33,836 1.00 (ref. cat.) 1.00 (ref. cat.)
Lipophilic user 226 3,030 7,437 0.83 (0.72,0.96) 0.01 0.90 (0.74,1.11) 0.33
Hydrophilic non-user 1,062 13,434 37,389 1.00 (ref. cat.) 1.00 (ref. cat.)
Hydrophilic user 128 1,706 3,884 0.95 (0.79,1.14) 0.57 0.97 (0.76,1.24) 0.82
All-cause mortality
Statin non-user 1,323 10,907 30,852 1.00 (ref. cat.) 1.00 (ref. cat.)
Statin user 684 4,233 10,421 0.95 (0.86,1.04) 0.27 0.88 (0.76,1.01) 0.07
1–12 prescriptions 365 1,358 5,713 0.92 (0.82,1.04) 0.20 0.86 (0.73,1.02) 0.08
≥12 prescriptions 319 2,875 4,708 0.98 (0.86,1.11) 0.74 0.90 (0.75,1.08) 0.27
Simvastatin non-user 1,527 12,115 33,845 1.00 (ref. cat.) 1.00 (ref. cat.)
Simvastatin user 480 3,025 7,428 0.93 (0.84,1.04) 0.21 0.87 (0.75,1.00) 0.06
Lipophilic non-user 1,525 12,110 33,836 1.00 (ref. cat.) 1.00 (ref. cat.)
Lipophilic user 482 3,030 7,437 0.94 (0.85,1.04) 0.23 0.87 (0.75,1.01) 0.072
Hydrophilic non-user 1,764 13,434 37,389 1.00 (ref. cat.) 1.00 (ref. cat.)
Hydrophilic user 243 1706 3884 0.94 (0.83,1.08) 0.41 0.93 (0.77,1.11) 0.40
aModel contains age, year of diagnosis, socioeconomic status, stage, grade, cancer treatment within 6 months (radiotherapy, chemotherapy, surgery), comorbidities
(prior to diagnosis, including acute myocardial infarction, congestive heart disease, peripheral vascular disaese, cerebral vascular accident, pulmonary disease, peptic
ulcer, liver disease, diabetes, renal disease), hormone replacement therapy use (in year prior to diagnosis), and other prescription medication use (tamoxifen, aromatase
inhibitor and low-dose aspirin and metformin, as time varying covariates)
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mortality risk with simvastatin use after diagnosis are in
line with mounting laboratory evidence suggesting the
pleiotropic effects of statins may be limited to lipophilic
statins. Lipophilic statins (such as simvastatin) have been
shown to decrease cell proliferation as well as inhibit
tumour growth in in vivo mouse mammary tumour
models [6]. In both the English and Scottish studies how-
ever, clear dose–response associations for stain use and
breast cancer mortality were not observed. A number of
studies have investigated statin use in relation to breast
cancer recurrence risk. Some [15, 18], but not all [16, 17]
have reported moderate reductions in breast cancer recur-
rence risk with statin use after diagnosis. The largest of
these studies, a Danish cohort of 18,769 women diagnosed
with stage I–III breast cancer, observed a significant
20 % reduction in the risk of breast cancer recurrence
risk with post-diagnostic statin use [15]. Interestingly,
in analysis by statin solubility, the reduction in breast
cancer recurrence was seen only for users of lipophilic
statins (e.g. simvastatin) [15].
In secondary analysis, we investigated the influence of
pre-diagnostic statin use in the year prior to diagnosis and
found a weak protective association with breast cancer-
specific mortality. Although comparable with results from
some previous population-based studies which observed
protective (although weak) effects against breast cancer
mortality [31, 32], it is unclear how clinically useful these
results are due to the difficulty of intervention during the
pre-diagnostic period. This is one of the few epidemiologic
studies to evaluate statin use and breast cancer progres-
sion according to hormone receptor status. We did not
find any difference in associations by ER status and results
were similar after adjustment for ER, PR and HER2 recep-
tor status. This contrasts preclinical evidence suggesting
that the anti-proliferative effect of statins may be stronger
for ER-negative tumours [5, 33].
Our study had a number of strengths and limitations.
We utilized data from a nationwide cancer registry to
identify all incident breast cancers diagnosed in Scotland
between 2009 and 2013 with follow-up of up to 6 years
after diagnosis. Linkages to mortality registries allowed
for robust identification of breast cancer deaths, al-
though some misclassification of cause is possible. Evi-
dence from methodological comparative studies suggest
that risk estimates are unlikely to be greatly affected
[34]. This study benefitted from available information on
important clinical factors including cancer stage, treat-
ments and comorbidities. In addition, availability of
breast cancer hormone receptor status facilitated further
sub-group analyses. Record linkage to national general
practitioner (GP) dispensed prescription records pro-
vided detailed information on the timing of medication
Table 3 Association between statin use before diagnosis and breast cancer-specific and all-cause mortality in patients with breast cancer
Breast cancer
mortality
Patients Person
years
Age-adjusted HR (95 % CI) P Adjusteda HR (95 % CI) P
[n = 12,231] [n = 12,230]
Breast cancer mortality
Statin non-user 834 9,200 29,298 1.00 (ref. cat.) 1.00 (ref. cat.)
Statin user 381 3,031 9,125 0.98 (0.86, 1.11) 0.71 0.85 (0.74,0.98) 0.03
Simvastatin non-user 963 10,175 32,229 1.00 (ref. cat.) 1.00 (ref. cat.)
Simvastatin user 252 2,056 6,193 0.95 (0.83,1.09) 0.48 0.87 (0.75,1.02) 0.08
Lipophilic non-user 961 10,168 32,212 1.00 (ref. cat.) 1.00 (ref. cat.)
Lipophilic user 254 2063 6,211 0.96 (0.83,1.10) 0.54 0.88 (0.76,1.02) 0.09
Hydrophilic non-user 1077 11,161 35,181 1.00 (ref. cat.) 1.00 (ref. cat.)
Hydrophilic user 138 1,070 3,242 1.02 (0.85,1.21) 0.87 0.90 (0.75,1.09) 0.28
All-cause mortality
Statin non-user 1,340 9,200 29,298 1.00 (ref. cat.) 1.00 (ref. cat.)
Statin user 691 3,031 9,125 0.96 (0.88,1.06) 0.41 0.75 (0.67,0.84) <0.001
Simvastatin non-user 1,567 10,175 32,229 1.00 (ref. cat.) 1.00 (ref. cat.)
Simvastatin user 464 2,056 6,192 0.95 (0.86,1.06) 0.38 0.83 (0.74,0.92) 0.001
Lipophilic non-user 1,564 10,168 32,212 1.00 (ref. cat.) 1.00 (ref. cat.)
Lipophilic user 467 2063 6211 0.96 (0.86,1.06) 0.42 0.83 (0.75,0.93) 0.001
Hydrophilic non-user 1,788 11,161 35,181 1.00 (ref. cat.) 1.00 (ref. cat.)
Hydrophilic user 243 1,070 3,242 0.98 (0.86,1.12) 0.77 0.81 (0.70,0.93) 0.002
aModel contains age, year of diagnosis, socioeconomic status, comorbidities (prior to diagnosis, including acute myocardial infarction, congestive heart disease,
peripheral vascular disaese, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease) hormone replacement therapy use
(in year prior to diagnosis), low-dose aspirin use and metformin (in year prior to diagnosis)
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Table 4 Sensitivity analysis of association between statin use and breast cancer-specific and all-cause mortality in patients with breast cancer
Medication user Medication non-user Age-adjusted
HR (95 % CI)
P Adjusted HR
(95 % CI)
P P
interactionCancer\all mortality Patients Person
years
Cancer\all mortality Patients Person
years
Cancer-specific mortality
Subgroup analyses: Statin users versus non-usersa
Stage 1–2 111 3,185 8,085 310 8,467 24,768 0.86 (0.69,1.08) 0.21 0.91 (0.68,1.21) 0.51
Stage 1–3 209 3,671 9,224 555 10,793 28,147 0.91 (0.77,1.08) 0.29 1.02 (0.83,1.26) 0.85
Diagnosed 2009–2010 207 2,187 6,820 569 5,211 19,746 0.79 (0.67,0.93) 0.06 0.77 (0.60,0.98) 0.04 0.08
Diagnosed 2011–2012 128 2,046 3,601 286 5,696 11,106 1.03 (0.83,1.28) 0.77 1.35 (0.98,1.85) 0.06
Estrogen receptor positive 243 3,655 9,079 552 8,995 25,600 0.88 (0.75,1.03) 0.11 0.92 (0.72,1.16) 0.48
Estrogen receptor negative 87 514 1197 279 1710 4705 0.95 (0.73,1.23) 0.69 1.06 (0.76,1.48) 0.72
Hormone receptors availableb 212 2610 6193 550 6918 18682 0.89 (0.75,1.05) 0.18 0.98 (0.77,1.25) 0.89
Using 1 year lagc 320 4067 9695 870 11073 31578 0.91 (0.80,1.04) 0.18 1.00 (0.78,1.28) 0.99
Adjusted for competing risk of deathd
Statin 335 4,233 10,421 855 10,907 30,852 0.88 (0.78, 1.00) 0.07 0.98 (0.81, 1.19) 0.88
Simvastatin 224 3,025 7,428 966 12,115 33,845 0.83 (0.72, 0.97) 0.02 0.91 (0.75, 1.12) 0.38
Use in first year after diagnosise
Statin user versus non-user 318 3,624 9,555 872 11,516 31,718 0.89 (0.78,1.02) 0.10 0.99 (0.82,1.21) 0.95
Simvastatin user versus non-user 210 2,470 6,569 980 12,670 34,704 0.86 (0.74,1.00) 0.05 0.95 (0.78,1.17) 0.65
All-cause mortality
Subgroup analyses: Statin users versus non-usersa
Stage 1–2 297 3,185 8,085 554 8,467 24,768 0.99 (0.85,1.14) 0.87 0.89 (0.74,1.06) 0.20
Stage 1–3 437 3,671 9,224 859 10,793 28,147 0.98 (0.87,1.10) 0.72 0.91 (0.78,1.06) 0.24
Diagnosed 2009–2010 456 2,187 6,820 871 5,211 19,746 0.94 (0.83,1.05) 0.26 0.79 (0.66,0.94) 0.01 0.38
Diagnosed 2011–2012 228 2,046 3,601 452 5,696 11,106 0.97 (0.82,1.14) 0.71 1.02 (0.79,1.30) 0.89
Estrogen receptor positive 549 3,655 9,079 946 8,995 25,600 0.98 (0.88,1.09) 0.70 0.85 (0.72,1.01) 0.06
Estrogen receptor negative 119 514 1197 324 1710 4705 0.99 (0.79,1.24) 0.92 1.00 (0.74,1.34) 0.98
Hormone receptors availableb
(and adjusted for)
400 2610 6193 806 6918 18682 0.95 (0.84,1.08) 0.43 0.89 (0.74,1.07) 0.23
Using 1 year lagc 648 4067 9695 1359 11073 31578 0.97 (0.88,1.07) 0.54 0.91 (0.75,1.10) 0.33
Cardiovascular deaths 142 4233 10421 132 10907 30852 3.21 (2.53,4.06) <0.001 1.07 (0.73,1.55) 0.74
Non-cardiovascular deaths 542 4233 10421 1191 10907 30852 1.36 (1.23,1.50) <0.001 0.86 (0.74,1.00) 0.06
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Table 4 Sensitivity analysis of association between statin use and breast cancer-specific and all-cause mortality in patients with breast cancer (Continued)
Use in first year after diagnosise
Statin user versus non-user 649 3,624 9,555 1,358 11,516 31,718 0.97 (0.88,1.07) 0.55 0.91 (0.79,1.06) 0.23
Simvastatin user versus non-user 445 2,470 6,569 1,562 12,670 34,704 0.96 (0.86,1.07) 0.47 0.89 (0.77,1.04) 0.15
aBased upon main time varying covariate analysis adjusted model contains age, year of diagnosis, socioeconomic status, stage, grade, cancer treatment within 6 months (radiotherapy, chemotherapy, surgery),
comorbidities (prior to diagnosis, including acute myocardial infarction, congestive heart disease, peripheral vascular disease, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal
disease) hormone replacement therapy use (in year prior to diagnosis) and other prescription medication use (tamoxifen, aromatase inhibitor, low-dose aspirin, and metformin as time varying covariates)
bModel contains all variables in a along with estrogen, progesterone and HER2 receptor status, where available
cStatin use modelled as a time varying covariate with a 1 year lag. Model contains all variables in 1 with prescription medication use all modelled with a 1 year lag (tamoxifen, aromatase inhibitor, low-dose aspirin use
and metformin)
dReported estimates are subdistribution hazard ratios and 95 % CIs
eModel contains age, year of diagnosis, deprivation, stage, grade, cancer treatment within 6 months (radiotherapy, chemotherapy, surgery), comorbidities (prior to diagnosis, including acute myocardial infarction,
congestive heart disease, peripheral vascular disease, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease) hormone replacement therapy use (in year prior to diagnosis) and
other prescription medication use in the first year after diagnosis (tamoxifen, aromatase inhibitor, low-dose aspirin use and metformin)
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usage which permitted temporal relationships to be ex-
plored as well as investigation by statin type. Misclassifi-
cation by over-the-counter use is limited in this study as
statins are not available over-the-counter (OTC) in
Scotland, apart from low dose 10 mg simvastatin which
became available in 2004 [35]. Similarly, OTC use of
low-dose aspirin is possible but previous investigation
within the General Practice Research Database found
that the majority of chronic aspirin use was captured by
prescription records [36]. Furthermore, valid treatment
risk estimates have been previously demonstrated when
there is potential for over-the-counter medication usage
[37]. We did not have information on medication adher-
ence but results were similar in analysis of multiple dis-
pensed prescriptions, in which adherence may be more
likely. Unfortunately, we could not examine the influence
of statins on breast cancer recurrence risk as recurrences
were not routinely captured within the Scottish Cancer
Registry. Finally, although we adjusted for a range of poten-
tial confounders, as with all observational studies, we can-
not rule out residual confounding by unrecorded (e.g. body
mass index) or incomplete variables (e.g. cancer stage).
Conclusion
In a large nationwide study of cancer-registry confirmed
breast cancer patients, we found little evidence of a pro-
tective association between statin use and cancer-specific
mortality. These findings will help inform the decision
whether to conduct randomised controlled trials of statins
as an adjuvant treatment in breast cancer.
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